Nuclidium AG

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2024-06-13

Patent Grants:

Last grant date:

2026-01-20

Top Inventors for applications by Nuclidium AG

These are the the leading inventors for applications assigned to Nuclidium AG:

Leila JAAFAR-THIEL 6 Erlangen, Germany
Francesco DE ROSE 5 Munich, Germany
Jacopo MILLUL 5 Basel, Switzerland
Melpomeni Fani 5 Basel, Switzerland

Luqman Mukhtar ISRAD 1 Erie, PA United States
Markus Josef BAIER 1 Teunz, Germany
Attila MOLNAR 1 Munich, Germany

Recent patent applications by Nuclidium AG

Nuclidium AG based in Basel, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-06-13

US20240189460A1

Human necessities

HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

#2 | 2024-05-30 ✅ Patent 12,527,885 granted on 2026-01-20

US20240173441A1

Human necessities

HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

#3 | 2024-05-30

US20240173440A1

Human necessities

HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

#4 | 2024-05-30 ✅ Patent 12,622,984 granted on 2026-05-12

US20240172953A1

Human necessities

HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

#5 | 2024-05-16

US20240161939A1

Physics

SOLID TARGET SYSTEMS FOR THE PRODUCTION OF HIGH-PURITY RADIONUCLIDE COMPOSITIONS

#6 | 2024-04-25 ✅ Patent 12,447,217 granted on 2025-10-21

US20240131203A1

Human necessities

FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

Also check out Nuclidium AG's (Basel, Switzerland) applicant profile with 7 patent applications submitted.

AssigneeID:

613531 ⎘